Trial · NCT05292209
RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring
NCT05292209, Phase 2, Recruiting, University of Utah
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring. Trials, record NCT05292209. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05292209
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring
- NCT number
- NCT05292209
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 78 participants, estimated
- Lead sponsor
- University of Utah
- Conditions
- Atrial Fibrillation Paroxysmal
- Interventions
- Riluzole 50 MG
- First posted
- 2022-03-23
- Last updated
- 2023-11-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Episodes of Tachycardia | 30 Days | Number of episodes of atrial fibrillation in 1 month between riluzole 50mg BID versus matching placebo; |
| Primary | Time to First Tachycardia Episode | 30 Days | Time to first episode of atrial fibrillation between riluzole 50mg BID and placebo |
| Secondary | Safety of Riluzole Pro-Arrhythmia | 30 Days | 1\. Pro-arrhythmia measured as number of episodes of V tachycardia over 30 days |
| Secondary | Safety of Riluzole Neutropenia | 30 days | Neutropenia measured by change on CBC \[baseline and 1-month end\] and patient signs and symptoms \[weekly phone call F/U\]). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05292209
GET https://conductscience.org/api/trials/v1/NCT05292209/registered